CME Group reported recent Q3 earnings of $2.68 per share, surpassing the Zacks Consensus Estimate of $2.63 by 1.90%, and revenues of $1.54 billion, which also beat estimates by 0.81% but represented a slight decline from $1.58 billion a year prior. Despite CME shares outperforming the S&P 500 year-to-date with a 15.7% gain, an unfavorable trend in earnings estimate revisions has resulted in a Zacks Rank #4 (Sell) for the stock, indicating potential near-term underperformance, further exacerbated by the Securities and Exchanges industry's position in the bottom 30% of Zacks-ranked industries.
CME Group reported Q3 EPS of $2.68, surpassing the Zacks Consensus Estimate of $2.63 by 1.90%, matching the prior year's EPS. Quarterly revenue reached $1.54 billion, exceeding consensus by 0.81% but representing a slight decline from $1.58 billion year-over-year. Despite this mixed revenue performance, CME shares have outperformed the S&P 500 year-to-date, gaining 15.7% against the index's 14.5%. Despite recent beats, the sustainability of CME's stock movement hinges on management's commentary and future earnings expectations. The company's earnings estimate revisions trend was unfavorable prior to this release, leading to a Zacks Rank #4 (Sell) for the stock. This rank suggests potential near-term underperformance, contrasting with the historical outperformance. Further compounding the cautious outlook, the Securities and Exchanges industry, to which CME belongs, is currently ranked in the bottom 30% of over 250 Zacks industries. Research indicates that industries in the top 50% significantly outperform those in the bottom 50%. This broad industry weakness could act as a material headwind for CME's stock performance, irrespective of individual company results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.30
Ticker Sentiment
